Confirmed
Clinical problem, proposed biomarker rationale, target users, and intended care settings.
Evidence
Building the evidence before making the claim.
A staged programme designed to test scientific feasibility, measurement repeatability, calibration, usability, clinical performance, and health-system fit.
Evidence dashboard
What is known, what is being tested, what comes next.
In testing
Signal detectability, measurement geometry, prototype components, site selection, and algorithm performance.
Not yet established
Diagnostic accuracy, clinical thresholds, result time, performance across patient groups, regulatory classification, and commercial specifications.
Next
Calibration protocol, reference testing strategy, ethics and regulatory pathway, pilot-site requirements, and usability study plan.
Studies & milestones
A public record of responsible progress.
We publish status, not unverified findings. Confidential methods and provisional IP stay offline.
Complete
Needs finding
Problem framing around late haemoglobin signals and blood-draw friction in ANC.
In progress
Optical feasibility
Benchtop signal work and differential wavelength exploration at 407 / 425 nm.
In progress
Prototype integration
Electronics, software, UI, and form-factor pairing for reader and pad.
Planned
Calibration study
Map device signal to accepted laboratory ZPP reference methods.
Planned
Usability evaluation
Frontline workflow, positioning, and repeatability in clinic-like settings.
Planned
Regulatory consultation
Classification, risk management, and evidence-planning discussions.
Development roadmap
A staged path to evidence.
Phase 0
Benchtop signal feasibility and tissue-model testing.
Phase 1
Integrated prototype, electronics, software, and user interface.
Phase 2
Calibration against accepted laboratory reference methods.
Phase 3
Usability, repeatability, and early clinical feasibility.
Phase 4
Performance studies, regulatory submission, and implementation planning.
Development-stage notice: ZAWADI is under active validation. Not a diagnostic substitute. Regulatory status: Research and development programme — not submitted for regulatory clearance and not offered for clinical diagnosis or commercial use.